IP Library Granted Patent US 11,504,369
Granted Patent B2
US 11,504,369 · App. 16/825,324 · Granted Nov 22, 2022

Cytosine-based TET enzyme inhibitors

Inventors: Andrew Kennedy (Lewiston, ME); Gabriella N. L. Chua (San Francisco, CA); Kelly L. Wassarman (Brighton, MA); Haoyu Sun (Beijing, CN)
Assignee: President and Trustees of Bates College
A61K31/513
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,504,369
App. No.
16/825,324
Granted
Nov 22, 2022
Kind
B2
Abstract

Provided herein, in some embodiments, are cytosine analogs, compositions comprising cytosine analogs, and methods of use for inhibiting a Ten-eleven translocation (TET) enzyme.

Claims (18)

1. A composition comprising a cytosine analog of forma I

or a pharmaceutically acceptable salt thereof,

wherein R 1 is independently selected from the group consisting of hydrogen, halogen, and an unsubstituted methyl, and

wherein R 2 is selected from the group consisting of an optionally substituted phenyl or pyridyl group, and

wherein the cytosine analog is in an amount effective to inhibit a Ten-eleven translocation (TET) enzyme.

2. The composition of claim 1 , wherein R 1 is hydrogen.

3. The composition of claim 1 , wherein R 1 is halogen.

4. The composition of claim 1 , wherein R 1 is methyl.

5. The composition of claim 3 , wherein R 1 is Cl.

6. The composition of claim 1 , wherein R 2 is optionally substituted phenyl.

7. The composition of claim 6 , wherein the optionally substituted phenyl is substituted with halogen, optionally substituted C 1-6 alkyl, or phenyl.

8. The composition of claim 6 , wherein R 2 is unsubstituted phenyl, 4-chlorophenyl, 3-chlorophenyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, or 4-methylphenyl.

9. The composition of claim 1 , wherein R 2 is optionally substituted pyridyl.

10. The composition of claim 1 , wherein the cytosine analog of formula I is selected from the group consisting of:

and a pharmaceutically acceptable salt of one of the aforementioned compounds.

11. A method for inhibiting a Ten-eleven translocation (TET) enzyme, the method comprising contacting the composition of claim 1 with the TET enzyme.

12. The method of claim 11 , wherein the TET enzyme is TET1, TET2 or TET3.

13. The method of claim 11 , wherein the contacting occurs in vitro or in vivo.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 2, 2023
From: BATES COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065091/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: KENNEDY, ANDREW; CHUA, GABRIELLA N. L.; WASSARMAN, KELLY L.; SUN, HAOYU
To: PRESIDENT AND TRUSTEES OF BATES COLLEGE
Reel/Frame 055327/0342 →
Continuity (2)
Provisional Application 62822774 · Mar 22, 2019
Related Publication 20200316069A1 · Oct 8, 2020